Related Experiment Videos

Reactive perforating collagenosis associated with diabetes mellitus

S C Poliak, M G Lebwohl, A Parris

The New England Journal of Medicine

|January 14, 1982

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

The British journal of dermatology·2021

Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019

See all related articles